课题基金 / 基金详情

COVID-19 Supplement - GH16-006: Conducting Communicable Disease Research in Kenya

COVID-19 Supplement - GH16-006: Conducting Communicable Disease Research in Kenya
COVID-19 增补 - GH16-006:在肯尼亚进行传染病研究
批准号:
10223853
负责人:
M KARIUKI NJENGA
金额:
$197.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-30 至 2021-09-29

项目摘要

项目成果

M KARIUKI NJENGA的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Summary Washington State University (WSU) proposes research in Kenya to address 7 objectives in Component A, Communicable Disease, of RFA-GH-16-006. The research is organized into three projects that together address the following objectives: Project 1 (i) develop, maintain and expand surveillance systems combining population-based and facility-based demographic, morbidity and mortality surveillance; (ii) develop laboratory capacity and platforms for etiologic investigation and evaluation of novel diagnostic; Project 2 (iii) conduct studies to assess the disease burden, risk factors, and prevention of zoonotic infections; (iv) conduct surveillance and research on antimicrobial resistance; (v) conduct research on the epidemiology and ecology of arboviruses and their vectors; and Project 3 (vi) conduct socio-cultural research on knowledge, attitudes and practice related to infectious disease and acceptance of prevention methods; (vii) develop cost of disease and intervention estimates. To accomplish these objectives, WSU has assembled a team of 20 scientists derived from WSU, University of Nairobi (UON), Emory University, Kenya Medical Research Institute (KEMRI), Kansas State University, and the government of Kenya. In addition, we have enlisted the infrastructural support of KEMRI, UON, and Henry Jackson Foundation. Since 2001, CDC has managed the human demographic surveillance system, rural and urban population-based infectious disease surveillance in Kenya. These platforms and the supporting laboratories were designed to assist in determining the burden of diseases and in conducting disease intervention trials. Here, WSU proposes to start by managing the platforms as-is, but also pilot new approaches to promote their fiscal sustainability. Through the platforms and other surveillance approaches, WSU will investigate the burden and risk factors of endemic and emerging diseases and antimicrobial resistance. In addition, we will conduct intervention studies to address the threats, and engage the government of Kenya to share data and advocate for policy change. Social scientists will work with the disease research team to assess the perceptions of diseases and treatment options, as well as behaviors that may affect human-human and animal-human transmission. To assess the economic burden of disease and cost-effectiveness of interventions, both direct and indirect impacts will be considered. The outcome of this project will be better understanding of level of these threats, and development of interventions that result in improvement of the health of Kenyans and reduction in global health threats.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10893917
  • 项目类别:
  • 资助金额:
    $55.57万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
Emerging Infectious Diseases Research Center - East and Central Africa
  • 批准号:
    10464357
  • 项目类别:
  • 资助金额:
    $66.45万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10630848
  • 项目类别:
  • 资助金额:
    $12.0万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
GH21-003, Advancing Public Health Research in Kenya
  • 批准号:
    10472398
  • 项目类别:
  • 资助金额:
    $742.7万
  • 财政年份:
    2021
  • 负责人:
    M KARIUKI NJENGA
  • 依托单位:
国内基金
海外基金
芽孢杆菌TR19-1对魔芋腐皮镰刀菌拮抗机理研究
1H/19F多核MRI术中可视化免疫抑制巨噬细胞定位脑胶质瘤浸润边界
ATPIF1调节线粒体膜电位影响靶向CD19 CAR-T细胞抗肿瘤活性的作用及机制
  • 批准号:
    2026JJ80001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    钟根深
  • 依托单位:
CD19/BCMA双靶向CAR-NK细胞治疗难治性SLE:作用机制与临床前转化研究
  • 批准号:
    2026JJ81339
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    谢希
  • 依托单位: